Your browser doesn't support javascript.
loading
Serologic Response of 2 Versus 3 Doses and Intradermal Versus Intramuscular Administration of a Licensed Rabies Vaccine for Preexposure Prophylaxis.
Endy, Timothy P; Keiser, Paul B; Wang, Dongliang; Jarman, Richard G; Cibula, Don; Fang, Hengsheng; Ware, Lisa; Abbott, Mark; Thomas, Stephen J; Polhemus, Mark E.
Afiliación
  • Endy TP; Departments of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, USA.
  • Keiser PB; Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Wang D; Department of Public Health, State University of New York Upstate Medical University, Syracuse, New York, USA.
  • Jarman RG; Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Cibula D; Department of Public Health, State University of New York Upstate Medical University, Syracuse, New York, USA.
  • Fang H; Departments of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, USA.
  • Ware L; Institute for Global Heath and Translational Sciences, State University of New York Upstate Medical University, Syracuse, New York, USA.
  • Abbott M; Institute for Global Heath and Translational Sciences, State University of New York Upstate Medical University, Syracuse, New York, USA.
  • Thomas SJ; Institute for Global Heath and Translational Sciences, State University of New York Upstate Medical University, Syracuse, New York, USA.
  • Polhemus ME; Institute for Global Heath and Translational Sciences, State University of New York Upstate Medical University, Syracuse, New York, USA.
J Infect Dis ; 221(9): 1494-1498, 2020 04 07.
Article en En | MEDLINE | ID: mdl-31802120
BACKGROUND: The World Health Organization recommends intradermal (ID) administration of rabies vaccine for preexposure prophylaxis. METHODS: In a randomized trial in adults assigned to 1 of 6 treatment groups (ID vs intramuscular [IM], 2 vs 3 doses, and controls), rabies neutralizing antibody titers were measured to 1 year postvaccination. RESULTS: ID vaccination produced acceptable antibody levels in all subjects (2- and 3-dose groups). At day 365, acceptable levels were 40% for IM and 50% for ID 2-dose schedule, and 70% for IM and 60% for ID 3-dose schedule. CONCLUSIONS: ID rabies vaccination induces acceptable antibody titers at a fraction of the dose. CLINICAL TRIALS REGISTRATION: NCT02374814.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Rabia / Vacunas Antirrábicas / Anticuerpos Neutralizantes / Inmunogenicidad Vacunal Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Infect Dis Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Rabia / Vacunas Antirrábicas / Anticuerpos Neutralizantes / Inmunogenicidad Vacunal Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Infect Dis Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos